Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
14
University of California San Diego/Moores Cancer Center
La Jolla, California, United States
Institute for Drug Development Cancer Therapy & Research Center/The University of Texas Health Science Center
San Antonio, Texas, United States
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
Safety and tolerability in patients with hepatic impairment will be assessed by adverse events (AEs), serious adverse events (SAEs) and out of range lab values
Time frame: at completion of the study
To evaluate the preliminary anti-tumor activity which will be assessed by radiological scans every 6 weeks
Time frame: at completion of the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.